Actively Recruiting
The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease
Led by Fayoum University · Updated on 2025-09-11
90
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research investigates the relationship between serum levels of statins and SGLT2 inhibitors (SGLT2i) when used together in patients with ischemic heart failure. The study aims to understand how these drugs affect cholesterol, LDL, HDL, and triglyceride levels over time. Conducted by Fayoum University's Department of Cardiology, this prospective study involves 90 outpatient participants diagnosed with ischemic heart disease. Participants are divided into three groups of 30 each: one group takes statins, another takes SGLT2i, and the third group takes both medications. Blood samples are collected at the start and after three months to measure serum statin and plasma SGLT2i levels using high-performance liquid chromatography (HPLC). Researchers monitor the impact of each drug on the other and track changes in lipid profiles and any adverse effects. During the study, patients provide informed consent and attend scheduled visits for blood sampling and laboratory tests. The main outcome is to evaluate the combined effect of statin and SGLT2i therapy on ischemic heart disease after three months. Safety and side effects are also observed. The study spans from April to July 2024, ensuring detailed monitoring of participants' responses to the treatments.
CONDITIONS
Brief Title
"The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with ischemic heart failure by a primary care provider
- Patients assessed for the use of statin with SGLT2 inhibitors
- Adults aged 50 to 80 years
- Patients willing to provide written informed consent
You will not qualify if you...
- Patients with liver dysfunction
- Patients with renal dysfunction
- Patients with fungal infections
- Patients with coagulation disorders
- Patients using drugs that interact with SGLT2 inhibitors
- Patients who refuse to enroll or provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 3 months
Participants receive statin, SGLT2i, or both medications as prescribed to manage ischemic heart disease. Blood samples are collected to measure drug levels and monitor cholesterol and lipid profiles.
1 baseline visit and 1 follow-up visit
Trial Site Locations
Total: 1 location
1
Asmaa mohamed abdelkader
Al Fayyum, Faiyum Governorate, Egypt
Actively Recruiting
Research Team
R
Raghda Roshdy
M
Marwa Kamal
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here